Brief: Can-Fite’s Says Drug Approved For Compassionate Use Treatment Of Advanced Liver Cancer Patients In Romania
23/08/2022 12:33
Aug 23 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE’S DRUG NAMODENOSON APPROVED FOR COMPASSIONATE USE
TREATMENT OF ADVANCED LIVER CANCER PATIENTS IN ROMANIA
* CAN FITE BIOPHARMA LTD - PHASE III PIVOTAL STUDY IS OPEN
FOR
PATIENT ENROLMENT
Source text for Eikon: ID:nBw407rtca
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage